American Association for Cancer Research
10780432ccr153153-sup-160208_1_supp_3376478_835h2n.doc (692 kB)

Suppl Text and Figures from Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

Download (692 kB)
journal contribution
posted on 2023-03-31, 20:23 authored by Wolfgang Wick, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J. van den Bent, Martin J.B. Taphoorn, Jonathan Steuve, Alba A. Brandes, Marie-France Hamou, Antje Wick, Markus Kosch, Michael Weller, Roger Stupp, Patrick Roth, Vassilis Golfinopoulos, Jean-Sebastien Frenel, Mario Campone, Damien Ricard, Christine Marosi, Salvador Villa, Astrid Weyerbrock, Kirsten Hopkins, Krisztian Homicsko, Benoit Lhermitte, Gianfranco Pesce, Monika E. Hegi

Suppl. Materials and Methods; 5 Suppl. Figures; 2 Suppl Tables and List of Participating Investigators Supplementary Figure S1. Definition of MGMT cut-off with a safety margin. Supplementary Figure S2. Comparison of Overall Survival in patients with vs without markers assessments. Supplementary Figure S3. Visualization of markers analyzed in the mTOR signaling pathway from KEGG. Supplementary Figure S4. Forest plot molecular markers Supplementary Figure S5. Complete Graphical summary of consensus cluster analysis based on the matrix obtained by the reconstitution of the data in using Non-linear Iterative Partial Least Squares (NIPALS) algorithm.


Swiss National Science Foundation

Swiss Cancer Ligue




Purpose: EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter.Experimental Design: Patients (n = 257) fulfilling eligibility criteria underwent central MGMT testing. Patients with MGMT unmethylated glioblastoma (n = 111) were randomized 1:1 between standard chemo-radiotherapy with temozolomide or radiotherapy plus weekly temsirolimus (25 mg). Primary endpoint was overall survival at 12 months (OS12). A positive signal was considered >38 patients alive at 12 months in the per protocol population. A noncomparative reference arm of 54 patients evaluated the assumptions on OS12 in a standard-treated cohort of patients. Prespecified post hoc analyses of markers reflecting target activation were performed.Results: Both therapies were administered per protocol with a median of 13 cycles of maintenance temsirolimus. Median age was 55 and 58 years in the temsirolimus and standard arms, the WHO performance status 0 or 1 for most patients (95.5%). In the per protocol population, 38 of 54 patients treated with temsirolimus reached OS12. The actuarial 1-year survival was 72.2% [95% confidence interval (CI), 58.2–82.2] in the temozolomide arm and 69.6% (95% CI, 55.8–79.9) in the temsirolimus arm [hazard ratio (HR) 1.16; 95% CI, 0.77–1.76; P = 0.47]. In multivariable prognostic analyses of clinical and molecular factors, phosphorylation of mTORSer2448 in tumor tissue (HR 0.13; 95% CI, 0.04–0.47; P = 0.002), detected in 37.6%, was associated with benefit from temsirolimus.Conclusions: Temsirolimus was not superior to temozolomide in patients with an unmethylated MGMT promoter. Phosphorylation of mTORSer2448 in the pretreatment tumor tissue may define a subgroup benefitting from mTOR inhibition. Clin Cancer Res; 22(19); 4797–806. ©2016 AACR.

Usage metrics

    Clinical Cancer Research